The continued EGFR-TKI with cytotoxic chemotherapy at progression—poison or medicine?

Yoon, Shinkyo; Choi, Chang; Lee, Jae Cheol

doi:10.21037/tlcr.2018.03.23

Cited by 2 publications

(2 citation statements)

References 15 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continuation of osimertinib plus chemotherapy regimen may rescue these patients who have received sequential EGFR-TKI therapy owing to poor response to chemotherapy. Although the phase 3 IMPRESS study demonstrated that continuation of gefitinib plus chemotherapy did not provide a better OS compared with chemotherapy alone (HR: 1.44, 95% CI: 1.07-1.94, P=0.016, median OS: 13.4 vs. 19.5 months), it cannot be determined whether the same results can be inferred using irreversible EGFR-TKIs in terms of improved central nervous system efficiency [18].…”

Section: Discussionmentioning

confidence: 98%

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Tsai

Yang

et al. 2021

Lung Cancer

View full text Add to dashboard Cite

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment Po-Lan Su (Conceptualization) (Data curation) (Investigation) (Methodology) (Writing -review and editing), Jeng-Shiuan Tsai (Conceptualization) (Data curation) (Investigation) (Methodology) (Writing -review and editing), Szu-Chun Yang (Data curation) (Writing -review and editing), Yi-Lin Wu (Data curation) (Writingreview and editing), Yau-Lin Tseng (Data curation) (Writing -review and editing), Chao-Chun Chang (Data curation) (Writing -review and editing), Yi-Ting Yen (Data curation) (Writing -review and editing), Chia-Ying Lin (Data curation) (Writing -review and editing), Chien-Chung Lin (Conceptualization) (Data curation) (Investigation) (Methodology) (Writing -review and editing), Chin-Chou Wang (Conceptualization) (Data curation) (Investigation) (Methodology) (Writing -review and editing), Meng-Chih Lin (Data curation) (Writing -review and editing), Wu-Chou Su (Conceptualization) (Data curation) (Investigation) (Methodology) (Writing -review and editing)

show abstract

Section: Discussionmentioning

confidence: 98%

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Tsai

Yang

et al. 2021

Lung Cancer

View full text Add to dashboard Cite

show abstract

“…AEs are shown in (31). A meta-analysis showed that, in advanced NSCLC, the median survival time was 13.26, 13.52, and 12.58 months for gefitinib, erlotinib and icotinib, respectively (25).…”

Section: Aesmentioning

confidence: 99%

Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study

Zeng¹,

Yan²,

Chen³

et al. 2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are increasing considered for the tailored management of resectable non-small cell lung cancer (NSCLC). This study aimed to analyze the survival and toxicity profile of patients with EGFR mutation-positive NSCLC treated with adjuvant icotinib.Methods: This was a single-center retrospective study of patients with EGFR mutation-positive NSCLC who underwent R0 (microscopically margin-negative) resection and received adjuvant icotinib between November 2011 and December 2017. The outcomes included 2-year disease-free survival (DFS) rate, 3-year overall survival (OS) rates, DFS, OS, and adverse events (AEs).Results: A total of 86 patients receiving adjuvant icotinib were included. Their mean age was 59.7± 10.0 years, and 26 (30.2%) patients were male. The 2-year DFS rate was 86.7%, and the 3-year OS rate was 95.3% with adjuvant icotinib. DFS (P=0.044) and OS (P=0.003) are better in stage I/II disease than in stage III disease. There seems no differences in DFS and OS between patients with low or high preoperative CEA levels (cutoff of 5 ng/mL), patients with exon 19 or 21 EGFR mutation or patients with or without smoking history. The most common AEs with adjuvant icotinib were rash (83.7%) and diarrhea (19.8%). One (1.2%) patient-reported grade ≥3 AEs. No treatment-related death occurred.Conclusions: For patients with EGFR mutation-positive NSCLC, adjuvant icotinib might be associated with a promising survival benefit, with an acceptable toxicity profile.

show abstract

The continued EGFR-TKI with cytotoxic chemotherapy at progression—poison or medicine?

Abstract: et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutationpositive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses.

Cited by 2 publications

References 15 publications

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study

Contact Info

Product

Resources

About